UNIVERSITI TEKNOLOGI MARA

PREVALENCE OF CO-MORBIDITIES & RISK FACTORS FOR MULTIDRUG RESISTANCE AMONG TUBERCULOSIS PATIENTS IN INSTITUTE OF RESPIRATORY MEDICINE, KUALA LUMPUR

ALIA AZMI

Thesis submitted in fulfilment of the requirements for the degree of Master of Health Science

Faculty of Health Sciences

November 2013

AUTHOR'S DECLARATION

I declare that the work in this thesis was carried out in accordance with the regulations of Universiti Teknologi MARA. It is original and is the result of my own work, unless otherwise indicated or acknowledged as referenced work. This thesis has not been submitted to any other academic institution or non-academic institution for any degree of qualification.

I, hereby, acknowledge that I have been supplied with the Academic Rules and Regulations for Post Graduate, Universiti Teknologi MARA, regulating the conduct of my study and research.

Name of Student	:	Alia Azmi	

Student I.D. No. : 2011423974

Programme : Master of Health Science (HS 781)

Faculty : Health Sciences

:

:

Thesis Title

Prevalence of Co-Morbidities and Risk Factors for Multidrug Resistance among Tuberculosis Patients in Institute of Respiratory Medicine, Kuala Lumpur

.....

Hon Ami

Signature of Student :

Date

November 2013

ABSTRACT

the issue of Multidrug Resistant Tuberculosis (MDR-TB) was Globally, acknowledged as a threat to the successful prevention and treatment of TB. In Malaysia, TB remains a major health issue and incidence has been rising slowly for the past decade indicating poor success rate in current TB control programme. Currently, very little epidemiological data can be found regarding the situation of TB and MDR-TB in Malaysia. Therefore, this study aims to bridge the gap in information regarding TB and MDR-TB by identifying the population at risk. The objective of this study is also to identify the independent risk factors associated with MDR-TB in Malaysia. 477 TB patients from the Institute of Respiratory Medicine (IPR) were universally sampled based on the records of patients in 2010. Among 477 patients sampled, 67.9% were male with mean age 37.2 (SD 14.9). 30% of patients were foreign born with the majority were from Myanmar (14.9%), Indonesia (9.4%) and Bangladesh (2.7%). Prevalence of TB/HIV and TB/Diabetes among the patients sampled was 0.059 and 0.155 respectively. In multivariate analysis, BCG Status (AOR=0.292, 95%CI 0.13-0.67) was found to be a protective risk factor while history of previous TB (AOR=4.36, 95%CI 1.80-10.56) was a risk factor for MDR-TB. Whilst history of previous TB is a commonly acknowledged risk factor, the evidence of BCG as a protective factor for MDR-TB indicates that BCG vaccination is still a viable preventive measure. Association was found between BCG Status and foreign born patients (p-value < 0.01) indicating a need for active screening of immigrants.

ACKNOWLEDGEMENT

Heartfelt appreciation goes, first and foremost, to my supervisors, Assoc. Prof Rodziah Ismail, Khairil Anuar Md. Isa and Dr. Nurhuda Ismail whom have tirelessly guide and point me in the right direction, not to mention spending countless hours together from the initial stage of proposal, to data collection and finally the completion of this thesis.

I would also like to thank my family for the unfailing understanding especially in regards to the demands of the thesis on my time, your money and my general presence for the past two years.

To the staff of the Institut Perubatan Respiratori, Kuala Lumpur, many thanks for going out of their way in helping me during data collection. Not forgetting other lecturers and staff of the Department of Environmental Health, thank you for your helping hands. Regardless of the obstacle encountered, everyone was more than willing to assist. Many ideas were formed and input gathered during those coffee breaks at the pantry.

Last but not least, my friends and colleagues, especially the postgraduates, thank you for spending weekends helping me compute the data, for picking up the slack when I was unable to carry out my duties and for lending your ears. Whoever said that research is a solitary journey clearly has not had friends like all of you.

Thank you to everyone and for those not mentioned personally, all your names would probably have taken bigger space than the thesis itself.

CHAPTER ONE INTRODUCTION

1.1 INTRODUCTION

In the early 20th century, Tuberculosis (TB) was thought to have been almost eradicated thanks to the discovery of its treatment drugs. Yet, in 2010, the World Health Organization reported that approximately 8.8 million cases of TB were reported worldwide of which about 1.4 million resulted in mortality (WHO, 2011). It is clear that TB is still a threat and has caused a huge number of mortality now, and in the past.

Tuberculosis is a communicable disease caused by the bacterium *Mycobacterium tuberculosis*. The main target organ for this mycobacterium is the lungs. However, infections in other parts of the body are not uncommon. TB bacteria have been known to attack the kidney, spine and brain (CDC, 2010). The transmission of TB occurs in the air, hence it is known as an airborne disease. *Mycobacterium tuberculosis* can be transmitted during coughing, sneezing, speaking, thus infecting the people surrounding the patient.

The treatment of TB usually involves the injection of first-line and/or secondline of anti-tuberculosis drugs. Currently, the most common TB control and management programme is the Direct Observed Therapy, Short Course (DOTS) and so far, studies have indicated an increase in total success rate in the implementation of DOTS (Erhabor, *et al.*, 2003; Woldeyohannes, *et al.*, 2011).

However, poor management of TB control and treatment programme has resulted in the emergence of multi-drug resistance TB that threatens TB eradication programme (Sandhu, 2011). Resistance to an anti-tuberculosis drug occurs when Mycobacterium tuberculosis are able to withstand the attack of antibiotic (ALA, 2011). Since drugs used are not able to eradicate the bacteria, resistance will spread from one person to another, resulting in a Drug-Resistance Tuberculosis (DR-TB). In fact, a study reported a mere 37.1% of success rate for 202 Multi-Drug Resistance TB (MDR-TB) patients in 3 different hospitals (Jeon, *et al.*, 2011). Retreatment of the